药格局YaoGeJu

US Orange Book × China public records

China record gap list

Official names matched by active ingredients, dosage form and administration route. The default view shows drugs with zero in all four Chinese record counts.

Comparison generated: 2026/11/08 18:57

Read these limits

  1. US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
  2. The Orange Book lists holder-submitted patents and does not cover all related patents.
  3. Zero Chinese counts mean no match in the sources loaded by this site, not an absence of activity in China. Source dates appear below; trial coverage is limited to registration-number years 2025/2026.
  4. This page contains no sales or market-size data and cannot establish development value.

Four counts: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. API and trial counts are shown separately.

China · records loaded by this site · Maximum
Reset

0 drugs match

Showing 0 rows

Sorted by Latest listed patent expiration, Ascending; missing dates appear last.

No records match these filters. Change the filters to view other matched drugs.

All matched drugs ↗

Sources and dates

FDA Orange Book ↗
CDE acceptance and review
2026/11/08 06:44
Chemical Drug Catalog
2026/11/08 06:41
API registration records
2026/11/08 06:43
NHSA drug code database
2026/10/23
Trial registry
2026/11/08 16:57 · Incomplete coverage
FDA Orange Book
2026/11/06

Only records with official-name, dosage-form and route matches are listed; unmatched combinations are excluded.

Zero Chinese counts mean no match in the sources loaded by this site, not an absence of activity in China. Source dates appear below; trial coverage is limited to registration-number years 2025/2026.